|
|
|
|
| LEADER |
01655nam a22002775i 4500 |
| 001 |
000292720 |
| 005 |
20210923091707.0 |
| 007 |
cr nn 008mamaa |
| 008 |
170703s2017 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319568058
|
| 024 |
7 |
|
|a 10.1007/978-3-319-56805-8
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a TRAIL, Fas Ligand, TNF and TLR3 in Cancer /
|c edited by Olivier Micheau.
|
| 250 |
|
|
|a 1st ed. 2017.
|
| 260 |
# |
# |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2017.
|
| 300 |
|
|
|a XIII, 317 p. 40 illus., 35 illus. in color. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|v 12
|
| 505 |
0 |
|
|a Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer -- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer -- IAPs and Resistance to Death Receptors in Cancer -- Bcl-2 Proteins and TRAIL Resistance in Melanoma -- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4 -- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy -- Atypical Immune Functions of CD95/CD95L -- TLR3 is a Death Receptor Target in Cancer Therapy -- Fas/CD95, Lipid Rafts and Cancer -- Role of Sphingolipids in Death Receptor Signalling -- Post-Translational Modifications and Death Receptor Signalling -- System Modeling of Receptor-Induced Apoptosis.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
1 |
4 |
|a Cancer Research.
|
| 700 |
1 |
|
|a Micheau, Olivier.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|